Inhibition of mineralocorticoid receptor (MR) expression or treatment of hepatocytes with the MR antagonist spironolactone has been shown to enhance FGF21-mediated cardiac repair and reverse pathological remodeling following myocardial infarction (Greenberg et al., 2006; Sun et al., 2023). Here, FGF21 is linked to myocardial infarction.